department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Nereus · pharmadog

pharmadog
drugs
Nereus

drug

patient view →

tradipitant

Marketedupdated 2mo ago

by $VNDA Vanda Pharmaceuticals Inc.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Nereus

generic

tradipitant

indication

Motion Sickness

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 30, 2030

~4.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Aug 9, 2036method-of-use (U-4396)US 12318375
Mar 4, 2036method-of-use (U-4396)US 10772880
Mar 4, 2036method-of-use (U-4396)US 10821099
Mar 4, 2036method-of-use (U-4396)US 11324735

FDA exclusivities (1)

Dec 30, 2030NCENew Chemical Entity (5y)4.5y

Data sources

ClinicalTrials.gov

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 2

tagApproval4 co-mentions · 1 sources
tagSmall Molecule2 co-mentions · 1 sources

Trials studying tradipitant

phase3A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Userecruitingn=280
phase3Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sicknessactive not recruitingn=705
phase2A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Usecompletedn=124
—Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesisavailable
phase3Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesiscompletedn=992
phase2Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sicknesscompletedn=126
phase3Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sicknesscompletedn=316
phase3Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesisrecruitingn=100

more trials →